Introduction
Understanding the pharmacology of specific drugs is essential to providing effective, safe, and quality care. Apart from avoiding prescription errors, having an accurate medication history and its indications is key in evaluating other treatment options. For this paper, the drug under evaluation is amphotericin B, an antifungal approved by the United States Food and Drug Administration (FDA) for the treatment of invasive fungal infections (ClinicalInfo, 2023).
The drug is fungicidal or fungistatic, depending on fungal susceptibility and the concentration in body fluids, and does not affect viruses or bacteria. Amphotericin B can be used to manage and treat opportunistic fungal infections in children exposed to Human Immunodeficiency Virus (HIV), including leishmaniasis, cryptococcosis, histoplasmosis, coccidioidomycosis, candidiasis, and talaromycosis (ClinicalInfo, 2023). People with HIV usually have weakened immune systems, making them vulnerable to opportunistic infections. Healthcare providers use their knowledge of each medication and treatment plan to deliver care appropriately.
Causes and Various Types of Opportunistic Infections
The primary indication of amphotericin B is opportunistic fungal infections in patients with HIV. Opportunistic infections (OIs) are a primary cause of mortality and morbidity in children with malignant and nonmalignant diseases. These infections occur due to commensal organisms, bacteria, viruses, and fungi, which become pathogenic when a person’s immune system is impaired (Riccardi et al., 2019). The causative agents can spread through body fluids, contaminated water or food, and in the air. Additionally, severe infections resulting from common pathogens can lead to OIs.
Riccardi et al. (2019) classified OI as therapy-associated complications in people who need immunosuppressive treatment, particularly in children undergoing organ or bone marrow transplantation and those on long-term hospitalization. Amphotericin B is among the most effective drugs in treating infections in immunosuppressed patients. Different types of iatrogenic immune suppression and genetic host patterns can further determine the clinical features of OIs (Riccardi et al., 2019; The Well Project, 2023). Common OIs include candidiasis, coccidioidomycosis, talaromycosis, leishmaniasis, and cryptococcosis (ClinicalInfo, 2023). Some of these infections are fungal, and amphotericin B is an antifungal drug.
Early detection of the specific OI is key to determining whether amphotericin B will help treat the condition. People with HIV are at a heightened risk of OIs due to their weakened immune systems compared to other populations. The United States Centers for Disease Control and Prevention (CDC) defines people with a CD4 cell count of 200 or less and living with HIV as having acquired immunodeficiency syndrome (AIDS) (The Well Project, 2023).
HIV is transmitted person-to-person through vaginal, semen, and rectal fluid, blood, and breast milk. In 2021, the World Health Organization estimated that at least 1.2 million people in the United States live with HIV (Felman & Murphy, 2023). Typically, HIV spreads when certain body fluids come in contact with damaged tissues, the bloodstream through injection, and mucous membranes inside the mouth, rectum, penis, and vagina. Invasive fungal infections affect mucous membranes, and amphotericin B targets fungal cell membranes.
People at an elevated risk of getting infected include those with multiple sex partners and who reside in areas with high HIV rates. Another vulnerable population is children born to parents with HIV and individuals with a history of sexually transmitted diseases (STDs). Although STDs do not necessarily increase the risk of HIV transmission, they can cause other health problems. As articulated by Felman and Murphy (2023), when HIV attacks infection-fighting CD4 cells, it makes it challenging for the body to fight off various illnesses, including OIs.
While amphotericin B can treat opportunistic fungal infections, some patients may still get these infections if they are unaware that they are HIV positive and not getting treatment, or if they are receiving care. Still, it fails to control their health problem effectively. Although HIV medications can prevent the virus from damaging a patient’s immune system, the health problem can gradually destroy their immune system, and taking amphotericin B may be used to manage life-threatening fungal infections.
Treatment and Recommendations
While amphotericin B is effective in treating fungal infections, there are other medication options for OIs. Common antibiotics, antifungals, and antivirals for treating OIs include azithromycin, clarithromycin, acyclovir, fluconazole, and voriconazole. Fluconazole and voriconazole are considered effective antifungals for patients with invasive candidiasis, coccidioidomycosis, and cryptococcosis (Udawatte et al., 2020). Azithromycin and clarithromycin treat bacterial infections, such as STDs and respiratory tract infections, while acyclovir slows the growth and spread of various viruses. In one study, amphotericin B was found to have a stronger cytotoxic impact than voriconazole (Udawatte et al., 2020; Williams & Chiller, 2022).
Additionally, compared to amphotericin, there are few documented clinical breakthroughs in patients treated with fluconazole. Noël de Tilly and Tharmalingam (2022) found that Candida strains were resistant to fluconazole but not to amphotericin B. In addition to these medication options, antibiotic prophylaxis can be administered to prevent OI. Melkamu et al. (2020) highlighted that the rise of antiretroviral therapy (ARV) has resulted in a positive reduction of OIs in HIV patients. ARV brings CD4 levels to normal, improving a person’s immune system. However, some viruses may cause infection even with a high CD4 count.
For a positive medication response, patients must take ART as prescribed and follow up with subsequent tests to ensure their HIV status remains undetectable. This highlights the fundamental importance of sensitivity tests to identify underlying pathogens and health issues. Despite its effectiveness, amphotericin B specifically works for fungal infections, making it critical to consider other ways of managing OIs among patients with HIV (Udawatte et al., 2020).
In advanced cases, combining amphotericin B and other treatment options for OIs can have adverse side effects. Individuals exposed to OIs or living in areas with high HIV incidence rates need frequent screening. Healthcare providers may screen for STDs and OIs, and, based on diagnoses, may recommend vaccination to prevent some infections. For patients with HIV, infection can occur after completion of amphotericin B, and taking suppressive therapy can minimize recurrence.
Moreover, evidence-based interventions are crucial for providing effective support to those at risk of OIs by limiting reliance on ineffective treatment plans and instead incorporating new approaches to improve health outcomes. Safe sexual practices and compliance with treatment regimens can prevent OIs. Nonetheless, considering non-pharmacological options such as public health and social measures is equally important. As established by Groll et al. (2019), administering amphotericin B is one step to managing OI effectively, especially in patients with HIV.
In addition to medication, practicing personal safety when around infected individuals can help fight off OIs. Healthy lifestyle choices, such as regular exercise, proper hygiene, and a balanced diet, can strengthen a person’s immune system, making them less susceptible to OI. Untreated water, contact with an animal’s feces, unwashed and undercooked food, and unpasteurized dairy can cause OIs. Most importantly, the community should be empowered on the risks of OIs and HIV, the long-term effects, and the importance of early detection.
Pharmacology Aspects of Amphotericin B
Pharmacological Class and Indication
Investigating the pharmacology and pharmacogenetics of amphotericin B can help determine the right dosage for patients with OIs. Despite the surge in new treatment options for OIs, amphotericin B remains a standard treatment for fungal infections. The pharmacological class of amphotericin B is polyene, which is under antifungals.
Polyene antibiotics bind cholesterol and ergosterol in human and fungal cells, forming channels that allow leakage and inhibit fungal growth. Amphotericin B has high activity against various fungal species. For example, Blastomyces dermatitidis, Histoplasma capsulatum, Candida species, Rhodotorula, and Mucor mucedo are inhibited by the drug’s concentrations(DrugBank, 2024). While amphotericin is considered effective against fungi at certain clinical concentrations, the medication does not affect viruses, rickettsiae, or bacteria.
Pharmacodynamics, Mechanisms of Action, and Pharmacokinetics
Amphotericin B works by binding to ergosterol in fungi’s cell membrane for permeability. Ergosterol is a major sterol in the fungal membrane, making it a target site of the drug. As articulated by Groll et al. (2019), this will subsequently result in the leaking of intracellular components. Amphotericin B can be either fungicidal or fungistatic, depending on the recognized clinical concentration in body fluids and fungal susceptibility. Amphotericin B then binds to ergosterol, disrupting its membrane and ultimately causing cell death. This implies that the drug directly kills the fungus instead of inhibiting its growth.
The drug’s absorption rate is 100% with intravenous infusion, and its metabolism is exclusively renal (DrugBank, 2024). After administration, it is distributed from the predominant organ sites to other tissues in the brain, kidney, and lungs and excreted as an unchanged drug in feces and urine (Groll et al., 2019). Its broad spectrum of applications makes it effective for treating OIs. Moreover, the indication for amphotericin B is the treatment of life-threatening infections.
Side Effects, Adverse Effects, and Contraindications
Health providers administer amphotericin B intravenously due to the drug’s poor oral absorption. Noor and Preuss (2023) stated that approximately 80 percent of patients under this medication develop renal and infusion-related toxicity. This is attributed to the interaction between cholesterol in human cells and amphotericin B.
Among the adverse effects of the drug are fevers, anaphylaxis, hypomagnesemia and hypokalemia, nephrotoxicity, and long-term administration (Noor & Preuss, 2023). Noor & Preuss (2023) added that contraindications may entail a history of anaphylactic reaction to the drug. Therefore, healthcare providers must comprehensively review drug-to-drug interactions before administering amphotericin B.
Conclusion
Treatment optimization is essential for long-term adherence, safety, and efficacy. Access to effective, quality, and comprehensive treatment options is important to managing diseases. Important consideration should be given to patients with OIs due to the increasing number of patients with HIV. OI occurs frequently in people living with HIV since their weak immune system makes them more vulnerable to infections.
Various treatment options have been employed to manage OI in HIV patients effectively. Among these is amphotericin B, which offers an advantage in treating fungal infections. However, the side effects of amphotericin B, ranging from fever to hypomagnesemia, have challenged its effectiveness. Therefore, balancing pharmacological and non-pharmacological options is key to the management and prevention of the indicators of amphotericin B.
References
ClinicalInfo (2023). Amphotericin B – Patient | NIH. Clinicalinfo | Information on HIV/AIDS Treatment, Prevention and Research | NIH.
DrugBank. (2024). Amphotericin B. DrugBank Online | Database for Drug and Drug Target Info.
Felman, A., & Murphy, M. (2023). Explaining HIV and AIDS. Medical and Health Information.
Groll, A. H., Rijnders, B. J., Walsh, T. J., Adler-Moore, J., Lewis, R. E., & Brüggemann, R. J. (2019). Clinical pharmacokinetics, pharmacodynamics, safety and efficacy of liposomal amphotericin B. Clinical Infectious Diseases, 68(Supplement_4), S260-S274.
Melkamu, M. W., Gebeyehu, M. T., Afenigus, A. D., Hibstie, Y. T., Temesgen, B., Petrucka, P., & Alebel, A. (2020). Incidence of common opportunistic infections among HIV-infected children on ART at Debre Markos referral hospital, Northwest Ethiopia: A retrospective cohort study. BMC infectious diseases, 20(1), 1-12.
Noël de Tilly, A., & Tharmalingam, S. (2022). Review of treatments for oropharyngeal fungal infections in HIV/AIDS patients. Microbiology Research, 13(2).
Noor, A., & Preuss., C. V. (2023). Amphotericin B – StatPearls – NCBI bookshelf. National Center for Biotechnology Information.
Riccardi, N., Rotulo, G. A., & Castagnola, E. (2019). Definition of opportunistic infections in immunocompromised children on the basis of etiologies and clinical features: A summary for practical purposes. Current Pediatric Reviews, 15(4), 197-206.
The Well Project. (2023). What are opportunistic infections? The Well Project: Women and HIV.
Udawatte, N. S., Kang, S. W., Wang, Y., Arumugam, T. V., & Seneviratne, C. J. (2020). Predictive nephrotoxicity profiling of a novel antifungal small molecule in comparison to amphotericin B and voriconazole. Frontiers in Pharmacology, 11, 511.
Williams, S. L., & Chiller, T. (2022). Update on the epidemiology, diagnosis, and treatment of coccidioidomycosis. Journal of Fungi, 8(7).